David Clause, MD
Orthopaedic Surgery · Opelousas, LANPI 1295734465
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,768 of the $2,678 with a category attached, or 66.0%. Stryker accounts for 79.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,161 and has fallen 95.6% since, to $52 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in LA, where the typical reported total is $3,274.
Across 36 payments — averaging $74.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$2K
- AbbVie$260
- Pacira Pharmaceuticals Incorporated$84
- Organogenesis Inc.$78
- Amgen$56
- Pacira Therapeutics, Inc.$32
- plus $34 from 2 others
What the payments were for
- Travel & lodging$91034%
- Food & beverage$1,76866%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 26 | $2,135 |
| AbbVie | 2 | $260 |
| Pacira Pharmaceuticals Incorporated | 1 | $84 |
| Organogenesis Inc. | 2 | $78 |
| Amgen | 1 | $56 |
| Pacira Therapeutics, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,678 in reported general payments places this provider in the 45th percentile of 286 orthopaedic surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 11 | $4,503 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 121 | $1,100 |
| Meloxicam | 144 | $701 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 66 | $542 |
| Diclofenac Sodium | 28 | $208 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 89 | $195 |
| Methylprednisolone | 28 | $176 |
| Tramadol Hcl | 17 | $34 |
| Prednisone | 12 | $27 |
| Amoxicillin | 13 | $10 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Opelousas
- Christopher HarrodBaton Rouge$3M
- Vinod DasaKenner$1.9M
- Pierce NunleyShreveport$1.8M
- Jorge IsazaBaton Rouge$1.2M
- Neil MakiThibodaux$620K
- Robert ZuraNew Orleans$597K
- Kevin McCarthyBaton Rouge$594K
- Timmothy RandellAlexandria$498K
- Fernando SanchezNew Orleans$484K
- Robert EastonBaton Rouge$394K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.